SteraMist Disinfection news

TOMI Environmental Solutions, Inc.® ("TOMI") (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced that the Company has entered into a contract with Vizient, Inc. increasing TO Mi`s presence in the U.S. healthcare system. Vizient is the largest group purchasing organization (GPO) in the healthcare industry supplying around $100 billion in annual member purchasing volume. Vizient serves approximately 97% of the nation`s Academic Medica

FREDERICK, Md., March 13, 2023 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced it will report results for the fourth quarter ended December 31, 2022, after the close of the financial markets on Thursday, March 16, 2023 and will hold a conference call at 4:30 p.m. ET that day.

To participate in the call by phone, dial (877) 545-0523 approximately

FREDERICK, Md., Jan. 25, 2023 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, announces that TOMI will present its SteraMist brand of products at three upcoming International Society for Pharmaceutical Engineering (ISPE) Conferences in the first quarter of 2023: The ISPE Facilities of the Future Conference, to be held in Bethesda, MD, January 31-Febraury 1, 2023; the I

FREDERICK, Md., Jan. 17, 2023 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, announces that the National Health Services (NHS) Wales purchased SteraMist ionized Hydrogen Peroxide (iHP) technology further expanding presence in Great Britain.

NHS Wales is a publicly funded healthcare system in Wales that provides emergency services as well as primary, secondary,

MRSA, methicillin-resistant Staphylococcus aureus, occurs more frequently in the summer and fall, according to new research.

Dr. Leonard Mermel, lead author and medical director of the department of epidemiology and infection control at Rhode Island Hospital in Providence, and his team analyzed MRSA samples from the hospitals microbiology department that were taken over a 10-year period.

Their research, which was published in the journal PloS ONE, suggests that there were appr